Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jul 18;21(8):349–354. doi: 10.1038/cgt.2014.35

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Nature America, Inc.

This work is licensed under a Creative Commons Attribution 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/

PMC Copyright notice

Suppression of pulmonary metastasis from B16F10 tumor. (a) Schematic representation of treatment schedule: C57/BJ6 mice (n=6) were treated, that is, with anti-CD25 mAb, irrelevant IgG mAb or untreated 1 day prior to tumor inoculation and 4 days post tumor inoculation, 5 × 10⁵ B16F10 cells were inoculated subcutaneously to the mice and tumor volume was monitored. Tumors were treated with±pGmCSF-b7.1 or pMG when the tumors reached approximately 100 mm³ in volume. (b) Macroscopic image of lungs. (c) The number of surface metastases counted. The results represent those from four animals per group. (d) Lung weight measurements are presented as means±standard error of the mean. *pGmCSF-b7.1 and anti-CD25 mAb combinational treatment compared with pMG and anti-CD25, P<0.05.